Skip to main content
NUTXNutex Health Inc.Buy Wait5.6·$191.77-0.12%
Buy WaitModerate Confidence
Investment thesis

Nutex Health is a high-quality business with an excellent earnings track record, but the risk/reward has compressed near its 52-week high, leaving thin modeled upside despite a supportive short-squeeze setup.

Thesis pillars

  • High Quality Roe Cash ConversionStable
  • Thin Upside Asymmetry FailureStable
  • Earnings Beat Streak CatalystStable
  • +2 more pillars — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Nutex Health Inc. (NUTX) Stock Analysis

Range Bound setup · Temporary headwind edge

Buy WaitVALUE-TRAP 1/5ValueQualityShortAI GATE: FLAGGED — 1 riskModerate Confidence

Healthcare · Medical Care Facilities

Wait for pullback to $183.00. Weak momentum — blocks BUY_NOW at $191.77. Engine's entry $183.00 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Counterparty: HaloMD (exclusive IDR claims processor); Weak growth.

Nutex Health is a physician-led healthcare services company operating 26 micro-hospital and specialty hospital facilities across 12 states as of December 31, 2025, alongside a population health management division that manages four independent physician associations (IPAs) with... Read more

$191.77+25.2% A.UpsideScore 5.6/10#14 of 35 Medical Care Facilities
QualityF-score8 / 9FCF yield9.94%
Entry $183.00(Atr Pullback Sticky)Stop $165.93Target $240.12(analyst − 13%)A.R:R 1.7:1
Analyst target$276.00+43.9%5 analysts
$240.12our TP
$191.77price
$276.00mean
$310

Wait for pullback to $183.00. Weak momentum — blocks BUY_NOW at $191.77. Engine's entry $183.00 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Counterparty: HaloMD (exclusive IDR claims processor); Weak growth. Chart setup: RSI 57 mid-range, Bollinger mid-band. Exceptional fundamentals but wait for better entry timing. Score 5.6/10, moderate confidence.

Passes 6/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 63d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and news legal. Suitability: aggressive.

10-K grounded · weekly refresh

About Nutex Health Inc.

About Nutex Health Inc.

Nutex Health generated $875.3 million in total revenue during 2025, more than 82 percent higher than the $479.9 million reported in 2024, with $844.2 million coming from its hospital division and $31.1 million from population health management. The company operated 26 micro-hospital and specialty hospital facilities across 12 states as of December 31, 2025, employing 944 full-time staff, contracting more than 280 doctors, and partnering with over 3,600 physicians and specialists across its independent physician association (IPA) networks.

Nutex Health's hospital division operates as an out-of-network provider that generally lacks negotiated reimbursement rates with insurers, collecting more than 99 percent of net patient service revenue from insurers, federal agencies and other third-party payors rather than direct patient payments. New hospital locations are typically structured across three separately owned entities, a real estate entity, a physician LLC, and a hospital facility in which Nutex holds 60 percent or greater equity, with in-market physicians co-investing in each; many of these entities are controlled by Chairman and CEO Dr. Vo. The population health management division, through its Management Services Organization, manages independent physician associations in Los Angeles, Houston, South Florida and Phoenix, with the Los Angeles IPA alone counting over 230 primary care physicians, 2,800 specialists and roughly 32,750 enrolled patients.

Show full overview

Nutex Health's out-of-network reimbursement depends on a single vendor: HaloMD has handled, on an exclusive basis, all of the company's claims eligible for arbitration under the federal No Surprises Act since May 2024, submitting an estimated 50 to 60 percent of Nutex's medical claims through the Independent Dispute Resolution process in 2025, and Nutex has no contractual right to audit HaloMD's underlying methodology or filings. That dependency drew scrutiny after a July 22, 2025 short-seller report, built partly on insurer lawsuits accusing HaloMD of submitting arbitration-ineligible claims, sent Nutex shares down 16.4 percent in a single session, followed by a second critical report on November 25, 2025.

See also: Healthcare · Medical Care Facilities

From Nutex Health Inc.'s most recent 10-K filing, extracted July 6, 2026.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-09-03
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Nov 5, 202663d to earnings· next earnings call

Thesis

Rewards
V7 flight-to-quality bonus: +0.5 (Q=8.4 in RISK_OFF)
Sector modifier (Healthcare): +0.5
Strong earnings beat streak (3/4)
Risks
Concentration risk — Counterparty: HaloMD (exclusive IDR claims processor)
Weak growth
Negative momentum

Key Metrics

P/E (TTM)7.3
P/E (Fwd)9.4
Mkt Cap$1.3B
EV/EBITDA3.1
Profit Mgn21.2%
ROE64.6%
Rev Growth-13.6%
Beta1.99
DividendNone
Rating analysts11

Quality Signals

Piotroski F8/9MoatNarrow

Concentration Risks(10-K Item 1A)

  • HIGHcounterpartyHaloMD (exclusive IDR claims processor)
    10-K Item 1A: 'Since May 2024, HaloMD has handled, on an exclusive basis, all out-of-network claims made by Nutex that are eligible for arbitration under federal and state “no surprise” laws.'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

2 floor-breakers·1 ceiling hit

Revenue shrinking — -13.6% YoY. Growth thesis broken unless recovery story develops.static

Revenue Growth
0.0
Declining revenue: -14%
Low model confidence on this dimension (33%).

Momentum below the gate floor. Component breakdown shows what dragged the score down.static

Macd
0.0
Volume
0.0
Obv
1.0
Rsi
5.5
Ma Position
9.0
Volume distribution (falling OBV)Above 200-day MA
GatesMomentum 3.1<4.5NEWS LEGALA.R:R 1.7 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 63d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRange BoundSuitability: Aggressive
RSI
57 · Neutral
20D MA 50D MA 200D MAGOLDEN CROSSSupport $152.38Resistance $200.00

Price Targets

$166
$183
$240
A.Upside+25.2%
A.R:R1.7:1

Position Sizing

ConvictionHigh conviction
Suggested %1.3%
Max %2.6%
RegimeRisk-Off

Risk Alerts

! momentum at 3.1 (below the engine's 4.5 threshold)
! NEWS:LEGAL
! News gate: flagged (1 risks, 0 concerns)

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-11-05 (63d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is NUTX stock a buy right now?

Wait for pullback to $183.00. Weak momentum — blocks BUY_NOW at $191.77. Engine's entry $183.00 (Atr Pullback Sticky) is the shallowest technical level that clears the 2:1 A.R:R minimum. Key risks: Concentration risk — Counterparty: HaloMD (exclusive IDR claims processor); Weak growth. Chart setup: RSI 57 mid-range, Bollinger mid-band. Exceptional fundamentals but wait for better entry timing. Target $240.12 (+25.2%), stop $165.93 (−15.6%), A.R:R 1.7:1. Score 5.6/10, moderate confidence.

What is the NUTX stock price target?

Take-profit target: $240.12 (+25.2% upside). Target $240.12 (+25.2%), stop $165.93 (−15.6%), A.R:R 1.7:1. Stop-loss: $165.93.

What are the risks of investing in NUTX?

Concentration risk — Counterparty: HaloMD (exclusive IDR claims processor); Weak growth; Negative momentum.

Is NUTX overvalued or undervalued?

Nutex Health Inc. trades at a P/E of 7.3 (forward 9.4). TrendMatrix value score: 9.3/10. Verdict: Buy (Wait for Entry).

What do analysts say about NUTX?

11 analysts cover NUTX with a consensus score of 4.1/5. Average price target: $276.

What does Nutex Health Inc. do?Nutex Health is a physician-led healthcare services company operating 26 micro-hospital and specialty hospital...

Nutex Health is a physician-led healthcare services company operating 26 micro-hospital and specialty hospital facilities across 12 states as of December 31, 2025, alongside a population health management division that manages four independent physician associations (IPAs) with about 38,000 enrolled members. The company generated $875.3 million in total revenue in 2025, up from $479.9 million in 2024, with $844.2 million from the hospital division; more than 99% of hospital net patient service revenue is paid by insurers, federal agencies and other third parties rather than patients directly.

Related stocks: ASTH (Astrana Health Inc.) · SRTA (Strata Critical Medical, Inc.) · STLN (Starling Oncology, Inc.) · AVAH (Aveanna Healthcare Holdings Inc) · GRDN (Guardian Pharmacy Services, Inc)
Home Stocks NUTX

Latest news

Latest News

Benzinga3d agoRISKLegal
TradingKey36d ago
TradingKey36d ago
Tech Times8d agoLegal
Yahoo Finance8d ago
AOL.com16d agoEarnings
Dars.gov.et51d ago
GuruFocus22d ago
Moomoo22d ago
Moomoo22d ago
Seeking Alpha22d ago
TradingView29d agoEarnings
MarketBeat29d ago
Zacks Investment Research29d ago
Zacks.com29d ago
PR Newswire2d agoLegal
Seeking Alpha65d ago
TradingKey37d ago
Yahoo Finance9d agoEarnings
Yahoo Finance9d agoAnalyst
Loading more...